Abstract
Objective: Since 1980, we have performed plasmapheresis before thymectomy for patients with generalized symptoms in order to protect against myasthenic crisis and to improve patient outcomes after thymectomy. The aim of this study was to evaluate an immediate and a long-term results of plasmapheresis before thymectomy for myasthenia gravis, retrospectively. Methods: Between January 1980 and December 1997, 51 patients with Osserman class IIA or IIB symptoms were treated with transsternal thymectomy. Nineteen patients (group 1) were treated with plasmapheresis before thymectomy and 32 patients (group 2) were treated with thymectomy alone. Results: In group 1, the time of plasmapheresis prior to thymectomy was 3.2±1.5. Nine (28.1%) patients in group 2 had crisis within 1 year after thymectomy as compared with only one (5.3%) patient in group 1 had crisis (p=0.049). There was no evidence of crisis within 30 days after thymectomy in group 1 and 5 (15.6%) patients in group 2 (p=0.0724). there was no postoperative death among patients in group 1. Responses to thymectomy in group 1 improved significantly, the improvement and pharmacologic remission rate had increased up to 100% and 79% at 5–7 years after operation, while the improvement and pharmacologic remission rate of group 2 had increased to 81.3% (p=0.0466 vs. group 1) and 50.0% at that time (p=0.0427 vs. group 1). Conclusions: The present study demonstrated that preoperative plasmapheresis may facilitate improved outcomes of patients with myasthenia gravis after thymectomy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borel CO. Management of myasthenic crisis: Continuous anticholinesterase infusions. Crit Care Med 1993; 21: 821–2.
Harati Y, Patten BM. Prednisone use in concurrent autoimmune diseases. Arch Neurol 1979; 36: 103–6.
Finn R, Coates PM. Plasma exchange in myasthenia gravis. Lancet 1977; 1: 190–1.
Kornfeld P, Ambinder EP, Papatestas AE, Bender AN, Genkins G. Plasmapheresis in myasthenia gravis: Controlled study. Lancet 1979; 2: 629.
Pinching AJ, Peters DK, Davis JN. Plasma exchange in myasthenia gravis. Lancet 1977; 1: 428–9.
Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986; 146: 1365–8.
Kamolvarin N, Hemachudha T, Ongpipattanakul B, Phanuphak P, Viddayakorn P, Sueblinvong T. Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis. Acta Neurol Scand 1989; 80: 324–6.
Blalock A, Harvey A, Ford F, Lilienthal J Jr. The treatment of myasthenia gravis by removal of the thymus gland. JAMA 1941; 117: 1529–31.
Monden Y, Uyama T, Nakahara K, Fujii Y, Hashimoto J, Ohno K, et al. Clinical characteristics and prognosis of myasthenia gravis with other autoimmune diseases. Ann Thorac Surg 1986; 41: 189–92.
Papatestas AE, Genkins G, Kornfeld P, Eisenkraft JB, Fagerstrom RP, Pozner J, et al. Effects of thymectomy in myasthenia gravis. Ann Surg 1987; 206: 79–88.
Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M, et al. Extended thymectomy for myasthenia gravis patients: A 20-year review. Ann thorac Surg 1996; 62: 853–9.
Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: Crisis and death. Ann N Y Acad Sci 1981; 377: 670–7.
Mahalati K, Dawson RB, Collins JO, Mayer RF. Predictable recovery from myasthenia gravis crisis with plasma exchange: thirty-six cases and review of current management. J Clin Apheresis 1999; 14: 1–8.
Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997; 25: 1228–35.
Blossom GB, Ernstoff RM, Howells GA, Bendick PJ, Glover JL. thymectomy for myasthenia gravis. Arch Surg 1993; 128: 855–62.
DeFilippi VJ, Richman DP, Ferguson MK. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1994; 57: 194–7.
Nieto IP, Robledo JP, Pajuelo MC, Montes JA, Giron JG, Alonso JG, et al. Prognostic factors for myasthenia gravis treated by thymectomy: Review of 61 cases. Ann thorac Surg 1999; 67: 1568–71.
Newsom-Davis J, Wilson SG, Vincent A, Ward CD. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979; 1: 464–8.
Seto M, Motomura M, Takeo G, Yoshimura T, Tsujihata M, Nagataki S. Treatment of myasthenia gravis: A comparison of the natural course and current therapies. Tohoku J Exp Med 1993; 169: 77–86.
Sellman MS, Mayer RF. Treatment of myasthenic crisis in late life. South Med J 1985; 78: 1208–10.
Yamamoto T, Vincent A, Ciulla TA, Lang B, Johnston I, Newsom-Davis J. Seronegative myasthenia gravis: A plasma factor inhibiting agonist-induced acetylcho-line receptor function copurifies with IgM. Ann Neurol 1991; 30: 550–7.
Yamamoto T, Sato T, Sugita H. Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis. Neurology 1987; 37: 1329–33.
Okada H, Moriwaki K, Sugahara S, Nakamoto H, Hosokawa T, Hamaguchi K, et al. Comparative study of clinical effects between plasma adsorption and double filtration plasmapheresis in patients with myasthenia gravis. Ther Apher 1997; 1: 343–7.
Shumak KH, Rock GA. Therapeutic plasma exchange. N Engl J Med 1984; 310: 762–71.
Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, najarian JS, et al. Transplantation of discordant xenografts: A review of progress. Immunol Today 1990; 11: 450–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nagayasu, T., Yamayoshi, T., Matsumoto, K. et al. Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis. Jpn J Thorac Caridovasc Surg 53, 2–7 (2005). https://doi.org/10.1007/s11748-005-1001-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11748-005-1001-y